ダーカム病の世界市場の予測（～2030年）

世界のダーカム病の市場規模は、予測期間にCAGRで6.76%の成長が見込まれています。

地域の考察

北米市場が2022年に最大の市場シェアを占めました。

欧州市場が第2位の市場シェアを占めています。ドイツ市場が最大の市場シェアを占めており、フランス市場が欧州でもっとも急速に発展しています。

アジア太平洋市場が2023年～2030年に重大な発展を示す見込みです。

当レポートでは、世界のダーカム病市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

• 概要
• 促進要因
  • 希少疾患の罹患率の増加
  • 研究開発活動の増加
• 抑制要因
  • この疾患についての人々の認識の欠如
• 機会
  • 戦略的取り組みの増加

第5章 市場要因の分析

• バリューチェーン分析
  • 研究開発
  • 製造
  • 販売、流通
  • 販売後調査
• ポーターのファイブフォース分析モデル
• 世界のダーカム病市場に対するCOVID-19の影響
  • サプライチェーンに対する影響
  • 需要に対する影響
  • 市場に対する影響

第6章 世界のダーカム病市場：治療別

• 概要
• 手術
• 投薬
  • 利尿薬
  • 非ステロイド性抗炎症薬
  • コルチコステロイド
  • その他
• 脂肪吸引
• 電気治療
• 鍼
• その他

第7章 世界のダーカム病市場：エンドユーザー別

• 概要
• 病院・診療所
• 外来手術センター
• その他

第8章 世界のダーカム病市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• その他

第9章 世界のダーカム病市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• その他の地域
  • 中東
  • アフリカ
  • ラテンアメリカ

第10章 競合情勢

• 概要
• 競合ベンチマーキング
• 財務マトリクス
  • 売上（2022年）
  • 研究開発費（2022年）

第11章 企業プロファイル

• PFIZER INC
• ABBVIE, INC
• JOHNSON & JOHNSON SERVICES, INC
• GLAXOSMITHKLINE PLC
• BAUSCH & LOMB INCORPORATED
• CALIWAY
• RAZIEL THERAPEUTICS LTD
• NIVARTA, INC.
• BHR PHARMACEUTICALS LTD
• NOVARTIS INTERNATIONAL AG

第12章 付録

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 GLOBAL: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 3 GLOBAL: DERCUM'S DISEASE MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 4 GLOBAL: DERCUM'S DISEASE MARKET, FOR MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5 GLOBAL: DERCUM'S DISEASE MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 6 GLOBAL: DERCUM'S DISEASE MARKET, FOR DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7 GLOBAL: DERCUM'S DISEASE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8 GLOBAL: DERCUM'S DISEASE MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10 GLOBAL: DERCUM'S DISEASE MARKET, FOR LIPOSUCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11 GLOBAL: DERCUM'S DISEASE MARKET, FOR ELECTROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12 GLOBAL: DERCUM'S DISEASE MARKET, FOR ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14 GLOBAL: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15 GLOBAL: DERCUM'S DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16 GLOBAL: DERCUM'S DISEASE MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18 GLOBAL: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19 GLOBAL: DERCUM'S DISEASE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20 GLOBAL: DERCUM'S DISEASE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22 GLOBAL: DERCUM'S DISEASE MARKET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 25 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 26 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28 US: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29 US: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 30 US: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31 US: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32 CANADA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33 CANADA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 34 CANADA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35 CANADA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36 EUROPE: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37 EUROPE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38 EUROPE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 39 EUROPE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40 EUROPE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41 GERMANY: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42 GERMANY: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 43 GERMANY: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44 GERMANY: DERCUM'S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2018-2030 (USD MILLION)
• TABLE 45 UK: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46 UK: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 47 UK: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48 UK: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49 FRANCE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50 FRANCE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 51 FRANCE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52 FRANCE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53 ITALY: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54 ITALY: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 55 ITALY: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56 ITALY: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57 SPAIN: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58 SPAIN: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 59 SPAIN: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60 SPAIN: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 63 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 67 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 68 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 69 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 70 CHINA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 71 CHINA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 72 CHINA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 73 CHINA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 74 INDIA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 75 INDIA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 76 INDIA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 77 CHINA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 78 JAPAN: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 79 JAPAN: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 80 JAPAN: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 81 JAPAN: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 82 AUSTRALIA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 83 AUSTRALIA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 84 AUSTRALIA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 85 AUSTRALIA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 86 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 87 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 88 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 89 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 90 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 91 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 92 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 93 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 94 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY REGION, 2018-2030(USD MILLION)
• TABLE 95 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 96 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 97 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 98 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 99 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 100 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 101 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 102 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 103 AFRICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 104 AFRICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 105 AFRICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 106 AFRICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 107 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
• TABLE 108 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
• TABLE 109 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
• TABLE 110 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
• TABLE 111 MAJOR PLAYERS IN THE GLOBAL DERCUM'S DISEASE MARKET
• TABLE 112 PFIZER INC: PRODUCTS OFFERED
• TABLE 113 ABBVIE, INC: PRODUCTS OFFERED
• TABLE 114 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED
• TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
• TABLE 116 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
• TABLE 117 3M: PRODUCTS/SERVICES OFFERED
• TABLE 118 RAZIEL THERAPEUTICS LTD: PRODUCTS OFFERED
• TABLE 119 NIVARTA, INC: PRODUCTS OFFERED
• TABLE 120 BHR PHARMACEUTICALS LTD: PRODUCTS OFFERED
• TABLE 121 NOVARTIS INTERNATIONAL AG: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL DERCUM'S DISEASE MARKET STRUCTURE
• FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DERCUM'S DISEASE MARKET
• FIGURE 5 DRIVER IMPACT ANALYSIS
• FIGURE 6 RESTRAINT IMPACT ANALYSIS
• FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL DERCUM'S DISEASE MARKET
• FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DERCUM'S DISEASE MARKET
• FIGURE 9 GLOBAL: DERCUM'S DISEASE MARKET, BY TREATMENT, 2022 & 2030 (USD MILLION)
• FIGURE 10 GLOBAL: DERCUM'S DISEASE MARKET, BY END-USER, 2022 & 2030 (USD MILLION)
• FIGURE 11 GLOBAL: DERCUM'S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2022 & 2030 (USD MILLION)
• FIGURE 12 GLOBAL: DERCUM'S DISEASE MARKET, BY REGION 2022 & 2030 (USD MILLION)
• FIGURE 13 GLOBAL: DERCUM'S DISEASE MARKET SHARE (%), BY REGION, 2022
• FIGURE 14 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY COUNTRY 2022 & 2030 (USD MILLION)
• FIGURE 15 NORTH AMERICA: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY 2022
• FIGURE 16 EUROPE: DERCUM'S DISEASE MARKET, BY COUNTRY 2022 & 2030 (USD MILLION)
• FIGURE 17 EUROPE: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY 2022
• FIGURE 18 ASIA PACIFIC DERCUM'S DISEASE MARKET SHARE, BY COUNTRY 2022 & 2030 (USD MILLION)
• FIGURE 19 ASIA PACIFIC: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY, 2022
• FIGURE 20 REST OF THE WORLD DERCUM'S DISEASE MARKET SHARE, BY REGION 2022 & 2030 (USD MILLION)
• FIGURE 21 REST OF THE WORLD: DERCUM'S DISEASE MARKET SHARE (%), BY REGION, 2022
• FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 23 SALES (USD MILLION), 2022
• FIGURE 24 R&D EXPENDITURE (USD MILLION), 2022
• FIGURE 25 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 26 PFIZER INC: SWOT ANALYSIS
• FIGURE 27 ABBVIE, INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 28 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
• FIGURE 30 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
• FIGURE 32 BAUSCH & LOMB INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 NIVARTA, INC: SWOT ANALYSIS
• FIGURE 34 NOVARTIS INTERNATIONAL AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS

Market Overview

The Dercum's Disease Market is anticipated to register a CAGR of 6.76% during the forecast period. The rising predominance of interesting diseases and expanding research and advancement exercises are driving market development.

Uncommon diseases, for example, adiposis dolorosa, and lipomas alongside the continuous Coronavirus pandemic, represent a significant weight worldwide. As per the NCBI study, held in February 2021, roughly 2500 individuals each year with free connective (fat) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum's disease. Moreover, a similar review recommended that the predominance of Dercum's disease is 0.64% in the populace, and the commonness of lipedema in the USA is believed to be 11% in ladies however the reach is 5 to 39%. A greater part of individuals with dercum's disease are ladies.

Besides, dercum's disease is portrayed by various, agonizing developments of greasy tissue (lipomas). In this way, the quantity of patients experiencing uncommon diseases is expanding universally. Besides, the rising instances of Coronavirus likewise fundamentally affect the market development of the dercum's disease. Such an ascent in the quantity of diseases cases is expected to worldwide expand the interest for dercum's disease.

Market Segmentation

The Market segments of Dercum's Disease, based on treatment, includes surgery, medication, liposuction, electrotherapy, acupuncture, and others.

The Dercum's Disease Market segmentation is based on end user that includes hospital & clinics ambulatory surgical centers others. Based on distribution channel the market is divided into hospital pharmacies, retail pharmacies, and others.

Regional Insights

The North America dercum's disease market represented the biggest market share in 2022. This is because of the ideal government act towards for the improvement of uncommon disease drug and gadgets as well as endorsement of medication in the district.

Europe dercum's disease market represents the second-biggest market share because of the research concentrates on through medical services administrative bodies for the therapy of dercum's disease and ideal approach and public undertakings systems. further, the Germany market of dercum's disease was credited to hold the biggest market share, and the France market of dercum's disease is supposed to quickest developing market in the European locale.

The Asia-Pacific dercum's disease market is supposed to develop at a critical offer from 2023 to 2030. This is because of the rising speculation, clinical preliminary examinations, and organizations' Research and development for medications to treat fat dolorosa in the Asia-Pacific locale.

The Rest of the World is portioned into the Middle East, Africa, and Latin America. The market of dercum's disease in the previously mentioned locales is probably going to observe development because of raising of assets and interests in the area through organizations.

Major Players

Key Companies in the market of dercum's disease include Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
  • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.4 FORECASTING TECHNIQUES
• 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.5.1 BOTTOM-UP APPROACH
  • 3.5.2 TOP-DOWN APPROACH
• 3.6 DATA TRIANGULATION
• 3.7 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF RARE DISEASES
  • 4.2.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF AWARENESS AMONG THE PEOPLE ABOUT THE DISEASE
• 4.4 OPPORTUNITIES
  • 4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 SALES AND DISTRIBUTION
  • 5.1.4 POST-SALES REVIEW
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL DERCUM'S DISEASE MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON DEMAND
  • 5.3.3 IMPACT ON MARKET

6 GLOBAL DERCUM'S DISEASE MARKET, BY TREATMENT

• 6.1 OVERVIEW
• 6.2 SURGERY
• 6.3 MEDICATION
  • 6.3.1 DIURETICS
  • 6.3.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUG
  • 6.3.3 CORTICOSTEROIDS
  • 6.3.4 OTHERS
• 6.4 LIPOSUCTION
• 6.5 ELECTROTHERAPY
• 6.6 ACUPUNCTURE
• 6.7 OTHERS

7 GLOBAL DERCUM'S DISEASE MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 HOSPITAL & CLINICS
• 7.3 AMBULATORY SURGICAL CENTERS
• 7.4 OTHERS

8 GLOBAL DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACIES
• 8.3 RETAIL PHARMACIES
• 8.4 OTHERS

9 GLOBAL DERCUM'S DISEASE MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 FINANCIAL MATRIX
  • 10.3.1 SALES (USD MILLION), 2022
  • 10.3.2 R&D EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

• 11.1 PFIZER INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 ABBVIE, INC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 KEY STRATEGIES
• 11.3 JOHNSON & JOHNSON SERVICES, INC
  • 11.3.1 COMPANY OVERVIEWS
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 GLAXOSMITHKLINE PLC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 BAUSCH & LOMB INCORPORATED
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTSS
  • 11.5.5 KEY STRATEGIES
• 11.6 CALIWAY
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS/SERVICES OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 RAZIEL THERAPEUTICS LTD
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 NIVARTA, INC.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 BHR PHARMACEUTICALS LTD
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY STRATEGIES
• 11.10 NOVARTIS INTERNATIONAL AG
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS